

REFERENCES

1. Shi Y, Wang E. Hepatosplenic T-cell lymphoma: A clinicopathologic review with an emphasis on diagnostic differentiation from other T-cell/natural killer-cell neoplasms. *Arch Pathol Lab Med*. 2015;139(9):1173–80.
2. Ferreri AJM, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma. *Crit Rev Oncol Hematol*. 2012;83(2):283–92.
3. Ashmore P, Patel M, Vaughan J, Wiggill T, Willem P, van den Berg E, et al. Hepatosplenic T-cell lymphoma: A case series. *Hematol Oncol Stem Cell Ther*. 2015;8(2):78–84.
4. Florena AM, Tripodo C, Porcasi R, et al. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement. *Leuk Lymphoma* 2006;47(January (1)):49–57.
5. Belhadj K, Reyes F, Farcet J. Hepatosplenic {gamma}{delta} T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. *Blood*. 2003;102(13):4261–9.
6. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. *Leuk Off J Leuk Soc Am Leuk Res Fund, UK*. 2000;14(6):991–7.